DrugPatentWatch

drugpatentwatch.com · New York City, United States of America

DrugPatentWatch provides data and analytics on pharmaceutical patents, exclusivity, and generic entry timelines, helping life sciences companies, investors, and legal professionals assess market opportunities and risks around drug patent expirations. The platform aggregates information from regulatory and patent sources to support competitive intelligence, portfolio strategy, and forecasting. It monetizes through subscription access to its online database and related data services.

Revenue
<$10M
Employees
1 - 50
Founded
2002
Headquarters
New York City, United States of America

DrugPatentWatch customers on Arbolus

Total customers 11 11 current · 0 former
Reviews growth 11 new reviews since May 2026

Customers who reviewed DrugPatentWatch

Seniority of DrugPatentWatch customers

Most people who reviewed DrugPatentWatch hold C-Suite roles (64%), followed by Director (36%).

  • C-Suite 64%
  • Director 36%

Customers sample

Revenue Leader C-Suite NPS 8
Executive C-Suite NPS 7 Undecided
Engineering Leader C-Suite NPS 10

Employer names and spend open once the report publishes.

What 11 Arbolus experts think of DrugPatentWatch

Overall sentiment: Neutral

NPS scores for DrugPatentWatch show a range of 6 to 10, with the majority (70%) in the 7-9 range. There is only one Promoter (NPS 10), several Passives, and two Detractors (NPS 6). Renewal intent for high spenders shows uncertainty, with one clear non-renewal and others unsure. Platform stickiness is strong among users with more than one year of implementation (60%), while about 20% are in early stages (less than 1 year). Key themes include moderate to strong satisfaction and extended implementation timelines, but some concerns over renewal intent in higher spend brackets.

Tell us when the DrugPatentWatch report publishes.

We'll email you once the full customer report is ready, with employer names, spend and every written answer. No account needed.

Sentiment

9 Net Promoter Score, from 11 scored reviews
  • Promoters 3
  • Passives 6
  • Detractors 2

Written answers and themes publish with the full report.

Renewal intent

Plan to renew 0%
  • Will renew 0
  • Undecided 2
  • Not renewing 1

Plan to renew, by seniority

  • C-Suite 0% 2 answers
  • Director 0% 1 answer
  • 6.5/10 Average score from undecided customers
  • 6/10 Average score from customers not renewing

For people who use DrugPatentWatch

Do you use DrugPatentWatch at work?

Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.

  • 11 customers of DrugPatentWatch have already contributed

Takes a few minutes. Your identity stays anonymous.